Sirnaomics Ltd
02257
Company Profile
Business description
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group’s operations and non-current assets are located at the United States of America and the mainland of the People’s Republic of China.
Contact
No.218 Xinghu Street
Unit 415, A4 Building
Suzhou Industrial Park
Suzhou
CHNT: +86 51262956283
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
37
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,135.57 | 91.75 | -1.12% |
| DAX 40 | 24,054.82 | 100.63 | -0.42% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,387.96 | 69.05 | -0.66% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |